A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
Status:
Completed
Trial end date:
2017-05-16
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in
Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.